Marathon Pharmaceuticals: Dynamic Medication and Distribution

Marathon Pharmaceuticals has been an innovator in medicine for a number of years. While many corporations look at large scale illness, Marathon recognizes the needs of all patients. They have been proponents of research and innovative science to treat rare conditions. A recent announcement was made that Marathon Pharmaceuticals has established a Bioscience center. This is an important facility to continue research about rare disorders and conditions that many people are suffering with. It will embody the organization’s mission of treating patients who have limited options due to contemporary research efforts.

 

Central nervous system diseases have few treatment options, as do many others. Gastrointestinal diseases and endocrine changes are also difficult to treat with conventional medicine. Marathon Pharmaceuticals has demonstrated a long-term interest in research and treatment of rare diseases. This has led them to establish the Bioscience center. Both biotechnology and innovative research will be part of the system. It will further target problems that are difficult to treat in traditional care facilities.

 

Many conditions may take a great deal of attention from healthcare professionals. Without the necessary treatment options available it becomes hard for the medical system to address patient needs. These include conditions that are hard to diagnose and treat because of limited options. Marathon Pharmaceuticals hopes to address these problems and help those who are suffering. They have established themselves at the forefront of their field and are innovators in pharmaceutical science.

 

The company has expanded significantly in recent years and has made multiple offices across the United States. Chicago, Northbrook and Los Angeles are just a few of the centers that they have developed. Their remarkable success and drive to achieve greater results have led Marathon Pharmaceuticals to be an important part of the industry.

 

Marathon Pharmaceuticals is a leader in the distribution of healthcare products and a pioneer in creating them. They have already funded several successful products in the past few years. High need medicine is the goal of this organization because of their consistent developments and interest in different kinds of care. Their interest in development and research are paramount and will create meaningful cures.

 

JEFF ARONIN: LEADING BIOSCIENCES INTO THE FUTURE

Jeff Aronin serves as the chief executive officer and chairman of Paragon Biosciences, a healthcare development and bio pharmaceutical investment firm based in Chicago, Illinois since 2010. In the world of bioscience investments, Jeff Aronin is one of the top players on the stage. His vision and strategic management have made Paragon Biosciences a tremendous force in the scope of medical investments.

Paragon is not Jeff’s first rodeo, however. Jeff has been involved as founder, co-founder, and chief executive officers of Castle Creek Pharmaceuticals, Ovation Pharmaceuticals, and has served as a consistent lecturer at the esteemed University of Chicago Booth School of Business. His aspirations is displayed through his history of leadership and innovation.

The most recent endeavor is MATTER, a group of investors in Chicago working to solve the challenges of healthcare and healthcare investment. The mission of MATTER is to help all stages of growth in a startup company solving issues surrounding healthcare, developing a synergy of respected health systems as well as executives to learn from each other and ultimately, help businesses thrive on challenge becoming more successful.

MATTER promises to bring an innovative approach to bio medical sciences which is the wheelhouse of Jeff and his team of investors.

Is Jeff Aronin taking the medical investment world by storm? It would indeed seem so through his ventures and notoriety. Recently, Jeff was recognized for his efforts by Insights Care magazine as one of the 20 Most Influential Leaders in Healthcare for 2018. Jeff has followed key principles in leadership, recruiting and retaining a highly skilled professional team that shares his vision for the future of biomedical sciences.

Jeff Aronin continuously raises the bar in biomedical investments and development. Starting out as a motivated investor throughout the Midwest, he has taken his leadership and integrity world wide, focusing on those businesses that promise a new horizon in biomedical sciences.

read more about jeff aronin below

https://www.paragonbiosci.com/news/2018/10/19/paragon-biosciences-announces-718-million-in-new-investment-for-portfolio-company-castle-creek-pharma

 

Talos Energy Hopes To Complete Deal With Pemex

Talos Energy has entered into early stage agreements with Pemex out of Mexico concerning a site located in the Gulf of Mexico. It is believed that the discovery may actually extend past the boundaries owned by their company. Pemex has never made an agreement of this kind with any company and will be contracted for 2 years.

These agreements are being made due to the suspicion of an extended oil field that affects the way drilling and pumping would take place. With this agreement in place, Talos Energy and Pemex will be able to both operate in the area. They are also in agreement to share their information in relation to the Zama discovery.

By working together, Talos Energy is hoping that the companies will be able to combine their efforts to produce the best possible results for the area. A working group between the companies will be established in order to facilitate this process. One of the risks being considered in the area between the 2 companies is the potential and severity of seismic activity in the area.

Talos Energy is driven by exploration in order to discover deposits of oil. Most of their focus takes place throughout Mexico and the United States. While the location in question with Pemex is located in one of the shallow water areas of the Gulf of Mexico, they also do a considerable amount of deepwater exploration as well.

The specific location of the area is in the Southeast Basin of Mexico. Before the deal can be completely finalized, it must be reviewed by the pending incoming government of Mexico. If approved, they are expected to be sitting on over a billion barrels of oil with their discovery.

Full  link : https://www.businesswire.com/news/home/20130206006701/en/Talos-Completes-Acquisition-Energy-Resource-Technology

Felipe Montoro Jens on the Discontinuations of Infrastructure Projects in Brazil

Ever since the financial crisis hit the State of Brazil, many sectors in the country have been trying to stay afloat. The infrastructure sector, in particular, has been faced with a myriad of challenges over the past year but still trying to cope. Some of the challenges include; technical issues, abandonment of projects by companies, financial and budgetary problems, issues of land ownership and also the issues of expropriation just to mention a few. After great efforts in an attempt to cope, these issues have finally caught up with the sector forcing several projects to be discontinued. The Brazilian National Confederation of Industries recently announced these discontinuations through Felipe Montoro Jens recently announced these discontinuations. Among the cut, short projects include; half a dozen port constructions, five railways and waterways, 30 highways, 16 airports, and the school construction project that Felipe Montoro was working on. More about Felipe Montoro Jens at infomoney.com

About Felipe Montoro Jens

Felipe Montoro Jens is a popular name in the Brazilian industry of finance. Jens is not only a finance guru but also an expert in the field of infrastructure and has been a consultant for more than a dozen projects in infrastructure in different parts of Brazil. Perhaps the reason for his popularity is the work he does in aiding business arrangements between the private industry and the Brazilian government. This arrangement is popularly known as a public-private partnership.

Education and career background of Felipe Montoro Jens

Felipe got his business degree from the prestigious Getulio Vargas Foundation. He later sought further education from the Thunderbird School of Global Management which is a subsidiary of the University of the State of Arizona. There he went through an intense training program in business management that opened doors for him in the industry.

After graduating, landing a job was a difficult task, so he accepted board membership requests from several organizations in various industries that helped him get well-endowed in different sectors. He then landed key positions in Enron, PricewaterhouseCoopers among other establishments leading to where he is currently.

Check: http://maringa.odiario.com/politica/2018/03/veja-com-felipe-montoro-jens-cidade-mineira-investe-em-ppp-para-estimular-o-lazer-e-a-pratica-de-atividades-fisicas-da-populacao/2476577/

 

 

 

Madison Street Capital Takes a New Direction

Recently, Madison Street Capital appointed a new Managing Director. Lawrence Alioto was chosen to help the firm take a new direction with their capital markets division. The purpose? It is now all about serving technology companies in the middle market. Technology is now one of the fastest growing industries, and as a result, financing is needed along with proper advising. This is where a firm like Madison Street Capital comes into play.

 

The New Managing Director, Lawrence Alioto, will now be there to advise these tech clients on their corporate structure and finance, along with M%A. The firm recognizes that it was essential to bring someone on board that was not only knowledgeable, but someone that had worked with clients before in the sector of technology. The CEO of the firm, Charles Botchway, has stated that he believes it was timely prior to the expansion in Austin.

 

While Alioto has experience in technology, his background is rooted in currency futures and as an options trader. Having worked for Paine Webber earlier in his career, he then chose to switch gears, and began working in private equity. Additionally, he also worked in the area of business development, and has also worked in a few select areas of government including security matters.

 

Alioto comes to the table with a lot to offer in the advising arena. Since 2013, he has been working with companies that are focused on wellness devices, and other areas of business. His interests although widely varied, have continued to lead him to working with investments and advising in the corporate marketplace.

 

Madison Street Capital is an international investment banking firm, but it is also known as a firm that strives for excellence in all areas of their business dealings. Their commitment to excellence is paramount, and they are highly regarded as one of the top firms by the M&A Advisor Awards. The firm has been nominated frequently, and they continue to grow in the global marketplace.

 

Madison Street Capital has focused their efforts on offering financial opinions, corporate finance, business valuations, and corporate financial advisory services. Whether the transaction is on their own soil or across the borders, Madison Street Capital is dedicated to working through each transaction with the highest integrity.

 

Visit http://madisonstreetcapital.org/ to learn more.

Dr. Anthony Constantinou Is Am Expert In Bayesian Networks

 

Dr. Anthony Constantinou of London heads the Department of Bayesian Artificial Intelligence, located at Queen Mary University in England. He is an assistant professor, researcher, and lecturer. Bayesian Networks are a graphical model which represents different variables and their dependence on each other during uncertain times. According to his research website, Constantinou uses his expertise for “sports, economics, medicine, and gaming.” His resume states that Dr. Constantinou analyzed the risks of betting, steel production, and agriculture.

 

Constantinou first earned a Bachelor of Science degree in Computer Science, with a concentration in Artificial Intelligence (2008). In 2009, he received his Master of Science in Artificial Intelligence with Robotics. He earned this degree with distinction. Anthony Constantinou studied for his doctorate between 2009-2012 and graduated with a Ph.D. in Bayesian networks for prediction, risk assessment, and decision making. He attended the University of Hertfordshire and the Queen Mary, University of London. Constantinou is a veteran of the Greek Cypriot National Guard and speaks native Greek and fluent English. Read This Article for additional information.

 

In addition to his studies, Constantinou worked as a researcher while studying for his doctorate. He interned and worked at AgenaRisk and currently works as a freelancer in his field. He has been named a fellow a few times. In August 2018, he became a Turing Fellow, in honor of Alan Turing. To date, he has written or co-written twenty professional articles, including “Pi-Football” A Bayesian Network Model for Forecasting Association Football Match Outcomes,” and “From Complex Questionnaire and Interviewing Data to Intelligent Bayesian Network Models for Medical Decision Support.”

 

You can read Constantinou’s works on his website on http://www.constantinou.Info

Roseann Bennett: Promoting Change In The Workplace

 

As a successful female entrepreneur, Roseann Bennett advocates for the fair treatment of women in the workplace. As a keen Champion Of Women’s Rights, Bennett often expresses her contempt for those who seldom make strides to uphold gender balances in professional settings. With that said, Bennett uses her status as a renowned businesswoman to stress the sanctity of supporting women in the workplace. According to Bennett, there are numerous clear-cut ways organizations can bolster women. Above all else, Bennett suggests that before instituting change, it’s vital for companies to realize that gender inequality is still prevalent.

 

When corporations are willing to accept this reality, it allows organic modifications to take shape. Setting goals are one surefire way to ensure that skewed ratios don’t materialize. Top-dog enterprises including GE and Accenture have adopted this method. In essence, they set goals to “hire a specific amount of women within a certain timeline.” GE, for instance, vowed to hire 20,000 women by 2020. This sound tactic guarantees that long-term changes remain in effect. Another approach Roseann Bennett recommends is encouraging transparent dialogue. Rather than writing gender inequality off as a taboo subject, Bennett suggests that employees should be allowed to discuss such affairs.

 

Moreover, Bennett is a firm believer in acknowledging the different experiences that men and women have in business settings. Bennett maintains that recognizing these diverse experiences helps uncover the external factors that promote gender imbalances. When companies get to the root of the problem, Bennett asserts that implementing change is far simpler. Finally, Bennett urges employers never to trivialize gender discrimination. Turning a blind eye to hard to swallow information is wholly unacceptable and does not bode well for equal treatment. With that said, Bennett claims that it’s exceedingly crucial to “never stop the dialogue.”

 

Roseann Bennett is the Executive Director and Co-Founder of the Center for Assessment and Treatment. The Center for Assessment and Treatment has helped a number of patients and their families through times of stress and trial. One of the benefits the center does offer is the ability to see patients that day instead of waiting for weeks. This very needed service underscores the need for this type of intervention. Many agencies do offer this type of therapy service, but the cost is sometimes prohibitive. Get Related Information Here.

 

More about Bennett on https://lionessmagazine.com/why-self-care-is-an-important-part-of-any-business-strategy/